Standard Cosentyx Dosing Schedule
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other indications, follows fixed dosing regimens based on condition and administration route (subcutaneous or IV). For plaque psoriasis in adults, it's a 300 mg dose (two 150 mg injections) at weeks 0, 1, 2, 3, 4, then every 4 weeks; maintenance stays at 300 mg every 4 weeks unless response is inadequate.[1][2]
Does Dosing Change Based on Patient Response?
No, Cosentyx posology is not routinely adjusted based on clinical response. Guidelines emphasize fixed schedules per label. If no improvement after 12-16 weeks (e.g., <50-75% PASI reduction in psoriasis), discontinue rather than titrate dose up. Higher starting doses (300 mg vs. 150 mg) were tested in trials but aren't response-driven adjustments post-initiation.[1][3]
Adjustments for Specific Patient Factors
Dosing alters only for body weight, age, renal/hepatic impairment, or formulation:
- Psoriasis in children (6+ years, ≥50 kg): 300 mg loading, then every 4 weeks; <50 kg uses 150 mg.
- No changes for mild-moderate renal/hepatic issues; avoid in severe cases.
- IV induction for ankylosing spondylitis: 10 mg/kg at weeks 0, 2, 4 (capped by weight bands).[2][4]
What Happens with Poor Response or Loss of Efficacy?
Switch or discontinue if inadequate response:
- Psoriasis: Reassess at 12 weeks; stop if <PASI50.
- Psoriatic arthritis: Evaluate at 12-24 weeks.
Anti-drug antibodies occur in ~5-10% but rarely prompt dose changes; monitor for infections instead.[3][5] Real-world data shows ~20-30% secondary failure rates, leading to switches (e.g., to IL-23 inhibitors) over dose tweaks.[6]
Comparison to Other Biologics
Unlike some (e.g., ustekinumab allows q8 vs. q12 week dosing based on response), Cosentyx sticks to fixed intervals. TNF inhibitors like adalimumab occasionally extend intervals on good response, but Cosentyx trials prioritized consistency.[3][7]
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: FDA Label for Secukinumab
[3]: EAE Psoriasis Guidelines (2021)
[4]: EMA Cosentyx Summary of Product Characteristics
[5]: Langley et al., NEJM 2014 (Pivotal Trial)
[6]: Real-World Evidence, J Am Acad Dermatol (2022)
[7]: Gottlieb et al., Lancet 2014 (Dosing Comparison)